Congenital cytomegalovirus (CMV) infection is a leading cause of developmental disabilities. In the United States during the period 1988-1994, approximately one-quarter of congenital CMV infections were attributable to primary maternal infection (n 5 8772), and three-quarters were attributable to non-primary maternal infection (n 5 29,918). Effective prevention strategies need to be developed for both primary and non-primary maternal infections.
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Human cytomegalovirus (CMV) is a common herpesvirus spreading between persons by close contact with infected body fluids, usually saliva, urine, blood, or genital secretions [1] . After primary infection (the first infection in life), CMV establishes a lifelong relationship with the infected host and undergoes latency and intermittent reactivation [1] . The infected host may also experience re-infection by another strain of CMV [2] . At any time during pregnancy, primary or non-primary maternal infection (ie, reactivation of infection or re-infection) can lead to CMV crossing the placenta and infecting the fetus, resulting in congenital CMV infection [3] .
Congenital CMV infection is the most common congenital viral infection and a leading cause of birth defects and developmental disabilities [4] . More than 30,000 children are born with congenital CMV infection each year in the United States. Of these, 4000-6000 children will develop permanent disabilities-most commonly, hearing loss, vision loss, or mental retardation-and 140 die from complications of the infection [5, 6] . More children are affected by CMV infection than by several more familiar congenital disorders, including Down syndrome, fetal alcohol syndrome, and spina bifida [4] .
Primary maternal infection during pregnancy has a much higher rate of mother-to-fetus transmission than does nonprimary infection (33% vs 1%) [5] and appears to be more likely to cause symptoms at birth and long-term disability than does non-primary maternal infection [2, 7] . Nevertheless, since the duration of pregnancy is relatively short, only a small percentage (1%-4%) of seronegative women acquire primary infection during pregnancy [8] . The majority of pregnancies in the United States (58%) occur in CMV seropositive women [8] . Thus, it is possible that more congenital CMV infections in the United States are attributable to non-primary maternal infection than to primary maternal infection. However, there are no published national estimates on the proportion of congenital CMV infections attributable to primary versus non-primary maternal infection. Prevention measures, such as vaccines or behavioral interventions, typically attempt to prevent primary maternal infections. If a substantial proportion of congenital infections are caused by non-primary maternal infections, then these may also need to be addressed by prevention measures.
METHODS
We estimated the proportion of congenital CMV infections attributable to primary versus non-primary maternal infection in the United States using summary data on mother-to-fetus transmission rates from a comprehensive literature review [5] and previously reported nationally representative data on ageand race-specific CMV seroprevalence [9] and seroincidence [8] during the period 1988-1994 (Table 1) . Table 1 displays how the estimates were derived, with the source and/or computation shown for columns A-F. We performed all calculations stratified by race/ethnicity and age. The annual number of women with primary infection during pregnancy (column E) was published previously [8] and was reprinted in Table 1 for comparison.
The 95% confidence intervals (CIs) for numbers of live-born children with congenital infection from non-primary maternal infection, numbers of women acquiring primary infection during pregnancy, and numbers of live-born children with congenital infection from primary maternal infection were calculated from Bayesian simulation with a normal assumption on their distributions. We did not include 95% CIs for other estimates because either their 95% CIs were very small or the estimates were based on or derived from census data. NOTE. Data are presented as number (95% confidence interval), unless otherwise indicated. a Adapted from Colugnati et al [8] .
b Current data are insufficient to accurately estimate the probability of non-primary maternal CMV infection among seropositive mothers or the probability of fetal infection given non-primary maternal infection. Thus, these 2 probabilities are combined as the probability of CMV transmission to the fetus from a seropositive mother. Transmission percentage is derived from summary data on mother-to-fetus transmission rates from a comprehensive literature review [5] .
c Probability of CMV transmission to the fetus following a primary maternal infection in a previously seronegative mother. Transmission percentage is derived from summary data on mother-to-fetus transmission rates from a comprehensive literature review [5] . 
RESULTS
We estimated that during the period 1988-1994, 38,640 (95% CI, 27,927-52,379) children per year were born with congenital CMV infection in the United States to non-Hispanic white, non-Hispanic black, and Mexican-American mothers ( Table 1) . Approximately one-quarter of these infections were attributable to primary maternal infection (n 5 8772) versus three-quarters that were attributable to non-primary maternal infection (n 5 29,918). The proportion of congenital infections attributable to primary maternal infection was 44% lower in Mexican-American mothers than in non-Hispanic black or non-Hispanic white mothers (14%, 25%, and 25%, respectively; P , .001). Among young mothers (aged 12-19 years), the attributable fraction from primary maternal infection was much lower among non-Hispanic white than among non-Hispanic black or Mexican-American mothers (5%, 56%, and 18%, respectively; P , .001). In contrast, in older age groups, the attributable fractions due to primary infection were higher among non-Hispanic white mothers than they were among non-Hispanic black and Mexican-American mothers (aged 20-29 years: 29%, 15%, and 16%, respectively; P , .001; aged 30-39 years: 24%, 11%, and 9%, respectively; P , .001).
DISCUSSION
We estimated that more children in the United States acquire congenital CMV infection from non-primary maternal infection than from primary maternal infection. This may seem counterintuitive, because primary maternal infection is associated with a much higher rate of vertical transmission than is non-primary infection [5] . However, many women of reproductive age are seropositive for CMV [9] (and thus at risk for non-primary rather than primary infection), and among seronegative women, rates of primary infection during pregnancy are low [8] . The attributable fraction of congenital CMV infection due to primary maternal infection varies substantially by race/ethnicity and age. These variations are the result of racial/ethnic and age differences in pregnancy rates, CMV seroprevalence, and risk among seronegative women of acquiring primary infection during pregnancy.
Although most congenital CMV infections result from nonprimary maternal infections, it is not known to what extent these are caused by viral reactivation versus re-infection with a different viral strain. Re-infection can be shown to be responsible in many instances [2] , but reactivation is difficult to demonstrate, because the absence of a detectable re-infection does not rule out the possibility that one is present, insofar as assays cannot detect all possible strains. Because maternal re-infections can cause congenital infections, avoiding exposure to CMV through behavioral changes should be beneficial for seropositive as well as seronegative pregnant women. In addition, although the occurrence of re-infections demonstrates that the normal immune response is not completely protective, prior seropositivity has been shown to reduce the risk of congenital infection [10] , suggesting that a vaccine-induced immune response could also be protective against congenital infection.
For various reasons, much of CMV research has focused on primary maternal infections and their impact. Our findings indicate, however, that there is also a need to better understand: (1) the biology and pathogenesis of non-primary infections;
(2) the frequency with which non-primary infections result in disability; and (3) the attributable fraction of non-primary infections caused by reactivation versus re-infection. Prevention measures, such as vaccines or behavioral interventions, might be evaluated not only for whether they prevent or attenuate primary infections but also for their potential benefit with regards to non-primary infections. Nevertheless, because primary infections are more likely than non-primary infections to cause symptoms at birth and long-term disability [2, 7] , especially severe disability, there remains an urgent need for interventions that can prevent primary CMV infections among pregnant women.
